Baloxavir Marboxil: An Original New Drug against Influenza

Baloxavir marboxil is a new drug developed in Japan by Shionogi to treat seasonal flu infection. This cap-dependent endonuclease inhibitor is a prodrug that releases the biologically active baloxavir acid. This new medicine has been marketed in Japan, the USA and Europe. It is well tolerated (more t...

Full description

Bibliographic Details
Published in:	Pharmaceuticals
Main Author:	François Dufrasne
Format:	Article
Language:	English
Published:	MDPI AG 2021-12-01
Subjects:	baloxavir marboxil influenza baloxavir acid prodrug cap-dependent endonuclease Xofluza
Online Access:	https://www.mdpi.com/1424-8247/15/1/28

Similar Items

Influenza A(H1N1)pdm09 Virus with Reduced Susceptibility to Baloxavir, Japan, 2024
by: Emi Takashita, et al.
Published: (2025-05-01)

Prophylactic Treatment with Baloxavir Protects Mice from Lethal Infection with Influenza A and B Viruses
by: Keita Fukao, et al.
Published: (2023-11-01)

Susceptibility of Influenza A, B, C, and D Viruses to Baloxavir
by: Vasiliy P. Mishin, et al.
Published: (2019-10-01)

Efficacy of baloxavir marboxil as a prophylactic against influenza among in-patients and analysis of influenza virus mutations in their isolates at a Japanese hospital during the 2023–2024 flu season
by: Akihide Fujii, et al.
Published: (2025-03-01)

Clinical efficacy of baloxavir marboxil versus oseltamivir in kidney transplant recipients with influenza
by: Jiali Jiang, et al.
Published: (2025-07-01)

Study on the clinical efficacy and safety of baloxavir marboxil tablets in the treatment of influenza A
by: Chaochao Qiu, et al.
Published: (2024-04-01)

Safety and effectiveness of baloxavir marboxil and oseltamivir for influenza in children: a real-world retrospective study in China
by: Xilin Ge, et al.
Published: (2024-07-01)

Real-world effectiveness and safety of Baloxavir Marboxil or Oseltamivir in outpatients with uncomplicated influenza A: an ambispective, observational, multi-center study
by: Jianpeng Cai, et al.
Published: (2024-07-01)

Evaluation of Baloxavir Marboxil and Peramivir for the Treatment of High Pathogenicity Avian Influenza in Chickens
by: Augustin Twabela, et al.
Published: (2020-12-01)

Validation of chromatographic method for impurity profiling of Baloxavir marboxil (Xofluza)
by: Wang Yiyun, et al.
Published: (2025-03-01)

The real-world safety of oseltamivir and baloxavir marboxil in children: a disproportionality analysis of the FDA adverse event reporting system
by: Wei Wei, et al.
Published: (2024-07-01)

Baloxavir Marboxil Polymorphs: Investigating the Influence of Molecule Packing on the Dissolution Behavior
by: Xinbo Zhou, et al.
Published: (2022-04-01)

Clinical efficacy and safety of baloxavir marboxil in the treatment of influenza: A systematic review and meta-analysis of randomized controlled trials
by: Yu-Chi Kuo, et al.
Published: (2021-10-01)

Determination of baloxavir marboxil in pharmaceutical preparations and spiked human plasma using its quenching action on acetoxymercuric fluorescein reagent: Assessment of greenness and whiteness
by: Mohamed S. Nasr, et al.
Published: (2024-06-01)

Safety evaluation of baloxavir marboxil: analysis and discussion utilizing real adverse events from the FAERS database
by: Xiaolong Lai, et al.
Published: (2025-05-01)

Baloxavir safety and clinical and virologic outcomes in influenza virus-infected pediatric patients by age group: age-based pooled analysis of two pediatric studies conducted in Japan
by: Nobuo Hirotsu, et al.
Published: (2023-01-01)

Ultrasensitive turn-off fluorescent sensor for estimation of the new influenza antiviral prodrug baloxavir marboxil in its pharmaceutical formulation
by: Amira S. Gouda, et al.
Published: (2025-01-01)

Safety analysis of Oseltamivir and Baloxavir Marboxil after market approval: a pharmacovigilance study based on the FDA adverse event reporting system
by: Yunsong Li, et al.
Published: (2024-05-01)

Prospective observational study of baloxavir marboxil in adults and adolescents with uncomplicated influenza from China
by: Guichan Liao, et al.
Published: (2023-11-01)

Factors associated with viral RNA shedding and evaluation of potential viral infectivity at returning to school in influenza outpatients after treatment with baloxavir marboxil and neuraminidase inhibitors during 2013/2014–2019/2020 seasons in Japan: an observational study
by: Jiaming Li, et al.
Published: (2023-03-01)

Characterization of the In Vitro and In Vivo Efficacy of Baloxavir Marboxil against H5 Highly Pathogenic Avian Influenza Virus Infection
by: Keiichi Taniguchi, et al.
Published: (2022-01-01)

Preparing for the Next Influenza Season: Monitoring the Emergence and Spread of Antiviral Resistance
by: Oh DY, et al.
Published: (2023-02-01)

Cost-Effectiveness of Baloxavir Marboxil Versus Oseltamivir or no Treatment for the Management of Influenza in the United States
by: Svenn Alexander Kommandantvold, et al.
Published: (2024-08-01)

Fast and Efficient Synthesis of Racemic Baloxavir Catalyzed by Strong Solid Acid under Microwave Conditions
by: Yiyun Wang, et al.
Published: (2022-06-01)

Drugs for Influenza Treatment: Is There Significant News?
by: Nicola Principi, et al.
Published: (2019-05-01)

Influenza: state-of-the-art and vaccination during COVID-19 pandemic
by: Editorial Article
Published: (2021-06-01)

Antiviral Treatment in Older Chinese Patient with SARS-CoV-2 and Influenza A Virus Co-Infection: A Case Series
by: Yang W, et al.
Published: (2023-07-01)

Antiviral Susceptibility of Swine-Origin Influenza A Viruses Isolated from Humans, United States
by: Rongyuan Gao, et al.
Published: (2024-11-01)

Prescription factors influencing baloxavir prescription during the 2018/2019 and 2019/2020 seasons: a administrative database study in Japan
by: Naomi Fujiwara, et al.
Published: (2023-02-01)

Cost-Effectiveness Analysis of Influenza Treatments in Japan Using a Transmission Model: The Impact of Baloxavir and Oseltamivir Shares
by: Ataru Igarashi, et al.
Published: (2025-08-01)

Low prevalence of influenza A strains with resistance markers in Brazil during 2017–2019 seasons
by: Thiago das Chagas Sousa, et al.
Published: (2022-09-01)

Comparison of the efficacy and safety of baloxavir versus those of oseltamivir in pediatric patients with influenza: a meta-analysis
by: Sheng Chen, et al.
Published: (2025-10-01)

Synthesis and Cap-Dependent Endonuclease Inhibition of Baloxavir Derivatives
by: Yiyun Wang, et al.
Published: (2023-06-01)

Generation and Characterization of Drug-Resistant Influenza B Viruses Selected In Vitro with Baloxavir Acid
by: Amel Saim-Mamoun, et al.
Published: (2022-09-01)

In Vivo Antiviral Activity of Baloxavir against PA/I38T-Substituted Influenza A Viruses at Clinically Relevant Doses
by: Takayuki Kuroda, et al.
Published: (2023-05-01)

Genomic Analysis of Influenza A and B Viruses Carrying Baloxavir Resistance-Associated Substitutions Serially Passaged in Human Epithelial Cells
by: Brady T. Hickerson, et al.
Published: (2023-12-01)

The Synergistic Effect of Baloxavir and Neuraminidase Inhibitors against Influenza Viruses In Vitro
by: Xiaojia Guo, et al.
Published: (2024-09-01)

Household Influenza Transmission and Healthcare Resource Utilization Among Patients Treated with Baloxavir vs Oseltamivir: A United States Outpatient Prospective Survey
by: Jennie H. Best, et al.
Published: (2024-03-01)

Innovations in the treatment and prevention of influenza in children and adolescents
by: Yu. V. Lobzin, et al.
Published: (2024-12-01)

Early Fever Resolution in Early Childhood Influenza Treated with Baloxavir Marboxil: A Retrospective Study Compared to Those with Oseltamivir
by: Keiko Nezu, et al.
Published: (2023-08-01)